Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in treating with EphA2 positive malignant glioma patients.


Clinical Trial Description

Chimeric antigen receptor (CAR) is a recombinant receptor with both antigen-binding and T cell activating functions. Chimeric antigen receptor T cell Immunotherapy has more advantages compared with conventional immunotherapy, especially in dealing with patients of hematologic malignancies and solid malignant tumors.This study design a novel specific Chimeric antigen receptor aiming at EphA2 antigen.After CAR-T cell infusion,At periodic intervals, the investigators will evaluate clinical symptoms Improved conditions of this disease.Through this study,the investigators will evaluate the safty and effectiveness of CAR-T cell immunotherapy in treating with EphA2 positive malignant glioma patients. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02575261
Study type Interventional
Source Fuda Cancer Hospital, Guangzhou
Contact
Status Withdrawn
Phase Phase 1/Phase 2
Start date September 2015
Completion date August 15, 2016

See also
  Status Clinical Trial Phase
Withdrawn NCT04406610 - CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients Phase 1/Phase 2
Withdrawn NCT03252171 - CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients Phase 1/Phase 2
Withdrawn NCT02723942 - CAR-T Cell Immunotherapy for HCC Targeting GPC3 Phase 1/Phase 2